858 On Other Exchanges
858 is not on other exchanges.

extrawell pharmaceutical (858) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EXTRAWELL PHARMACEUTICAL (858)

Related News

No related news articles were found.

extrawell pharmaceutical (858) Related Businessweek News

No Related Businessweek News Found

extrawell pharmaceutical (858) Details

Extrawell Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, and sells pharmaceutical products in the People’s Republic of China and Malaysia. It operates through Manufacturing, Trading, and Gene Development segments. The company offers Transfer Factor Oral Solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; and Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing. It also provides ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels; Feining Pian, which is used for the treatment of chronic cough, acute upper respiratory tract infection, infection associated with bronchitis, and emphysema; and YouHuanPing, a sustained-release tablet for sideropenic anemia. In addition, the company is involved in the marketing and distribution of imported pharmaceutical products, including GM-1 to treat lesions of central nervous system due to vascular or traumatic events and Parkinson's disease; Millibar for the treatment of high blood pressure; and Skin-Cap for use in the treatment of psoriasis, dandruff, dermatitis, atopic dermatitis, eczema, and tinea. Further, it engages in the commercial exploitation and development of genome-related technology; provision of agency services; and property investment business. Extrawell Pharmaceutical Holdings Limited is headquartered in Quarry Bay, Hong Kong.

238 Employees
Last Reported Date: 12/8/16

extrawell pharmaceutical (858) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.3M
Honorary Chairman and Chief Scientific Adviso...
Total Annual Compensation: --
Executive Director
Total Annual Compensation: $487.0K
Executive Director
Total Annual Compensation: $487.0K
Financial Controller, Joint Company Secretary...
Total Annual Compensation: $995.0K
Compensation as of Fiscal Year 2016.
extrawell pharmaceutical
Extrawell Pharmaceutical Holdings Ltd. Announces Unaudited Consolidated Earnings Results for the Half Year Ended Sept. 30, 2016

Extrawell Pharmaceutical Holdings Ltd. announced unaudited consolidated earnings results for the half year ended Sept. 30, 2016. For the six months, the company reported revenue of HKD 64,196,000 compared to HKD 81,634,000 a year ago. Profit before taxation was HKD 2,676,000 compared to loss of HKD 35,955,000 a year ago. Profit attributable to owners of the company was HKD 4,720,000 or 0.20 cents per diluted share compared to loss attributable to owners of the company of HKD 33,593,000 or 1.41 cents per basic and diluted share a year ago. Such turnaround from loss to profit was mainly the result of decrease in loss on fair value change of derivative component of the Group's investments in convertible bonds which was down from about HKD 63.2 million to HKD 23.7 million.

Extrawell Pharmaceutical Holdings Ltd. to Report Q2, 2017 Results on Nov 29, 2016

Extrawell Pharmaceutical Holdings Ltd. announced that they will report Q2, 2017 results on Nov 29, 2016

Extrawell Pharmaceutical Holdings Ltd., Board Meeting, Nov 29, 2016

Extrawell Pharmaceutical Holdings Ltd., Board Meeting, Nov 29, 2016. Agenda: To consider interim results of the Company and its subsidiaries for the six months ended 30 September 2016 and transacting other business, if any.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

858 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 858.
View Industry Companies

Industry Analysis


Industry Average

Valuation 858 Industry Range
Price/Earnings 12.3x
Price/Sales 5.1x
Price/Book 0.6x
Price/Cash Flow 8.9x
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact EXTRAWELL PHARMACEUTICAL, please visit www.extrawell.com.hk. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.